1. Home
  2. SKYE vs EXFY Comparison

SKYE vs EXFY Comparison

Compare SKYE & EXFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • EXFY
  • Stock Information
  • Founded
  • SKYE 2012
  • EXFY 2008
  • Country
  • SKYE United States
  • EXFY United States
  • Employees
  • SKYE N/A
  • EXFY N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • EXFY Computer Software: Prepackaged Software
  • Sector
  • SKYE Health Care
  • EXFY Technology
  • Exchange
  • SKYE Nasdaq
  • EXFY Nasdaq
  • Market Cap
  • SKYE 94.0M
  • EXFY 343.4M
  • IPO Year
  • SKYE N/A
  • EXFY 2021
  • Fundamental
  • Price
  • SKYE $2.73
  • EXFY $3.18
  • Analyst Decision
  • SKYE Buy
  • EXFY Buy
  • Analyst Count
  • SKYE 6
  • EXFY 4
  • Target Price
  • SKYE $18.67
  • EXFY $3.50
  • AVG Volume (30 Days)
  • SKYE 167.7K
  • EXFY 426.4K
  • Earning Date
  • SKYE 02-09-2025
  • EXFY 02-20-2025
  • Dividend Yield
  • SKYE N/A
  • EXFY N/A
  • EPS Growth
  • SKYE N/A
  • EXFY N/A
  • EPS
  • SKYE N/A
  • EXFY N/A
  • Revenue
  • SKYE N/A
  • EXFY $137,440,000.00
  • Revenue This Year
  • SKYE N/A
  • EXFY N/A
  • Revenue Next Year
  • SKYE N/A
  • EXFY $6.09
  • P/E Ratio
  • SKYE N/A
  • EXFY N/A
  • Revenue Growth
  • SKYE N/A
  • EXFY N/A
  • 52 Week Low
  • SKYE $2.25
  • EXFY $1.24
  • 52 Week High
  • SKYE $19.41
  • EXFY $4.13
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 37.40
  • EXFY 41.35
  • Support Level
  • SKYE $2.31
  • EXFY $3.07
  • Resistance Level
  • SKYE $3.04
  • EXFY $3.68
  • Average True Range (ATR)
  • SKYE 0.30
  • EXFY 0.17
  • MACD
  • SKYE 0.07
  • EXFY -0.08
  • Stochastic Oscillator
  • SKYE 44.68
  • EXFY 18.03

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.

Share on Social Networks: